PODD221118P00200000
| Previous close | 20.70 |
| Open | N/A |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | N/A |
| Expiry date | 2022-11-18 |
| Day's range | 20.70 - 20.70 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Simply Wall St.
Insulet (NASDAQ:PODD) shareholders are still up 307% over 5 years despite pulling back 9.2% in the past week
While Insulet Corporation ( NASDAQ:PODD ) shareholders are probably generally happy, the stock hasn't had particularly...
- Zacks
Insulet (PODD) Reports Pivotal Extended Phase Data for Omnipod 5
Insulet's (PODD) Omnipod 5 showed improved time in range and lower HbA1c for pre-school children during an extended phase of the previous pivotal trial.
- Business Wire
Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years
ACTON, Mass., June 03, 2022--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented new Omnipod® 5 Automated Insulin Delivery System (Omnipod 5) study results for very young children with type 1 diabetes. Omnipod 5, the first tubeless, wearable automated insulin delivery (AID) system in the U.S., significantly improved time in range and reduced HbA1c in children aged 2 through 5.9 yea
